

## ABT-737, Senolytic Bcl2 inhibitor

Catalog	Unit
TBI3661-5MG	5 mg
TBI3661-25MG	25 mg

### Product Details

**Formal Name:** 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-benzamide

**Molecular Formula:** C<sub>42</sub>H<sub>45</sub>ClN<sub>6</sub>O<sub>5</sub>S<sub>2</sub>

**Formula Weight:** 813.40

**CAS Number:** 852808-04-9


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 5 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years.



### Applications

Senolytic Bcl2 inhibitor

### Functions

Inhibitor of anti-apoptotic proteins from the Bcl family: Bcl-2, Bcl-X(L), and Bcl-w (K<sub>i</sub> < 1 nM) that causes regression of solid tumors in mice. Senolytic agent which disrupts aberrant p21 expression, inducing apoptosis in senescent cells, and enhancing liver regeneration in mice. Acts synergistically to reduce cell viability when combined with CDK inhibitor purvalanol A in preclinical models of acute myeloid leukemia (AML).

### Application Procedures

First dissolved in DMSO (up to 5 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**